A new drug for bladder cancer that returns after standard treatment
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called ATO-101™ for people whose bladder cancer has come back after standard treatments like BCG or mitomycin. The goal is to see if the drug is safe and may help control the cancer before you decide on more radical surgery to remove the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in generally good health, with a performance status of 0 or 1 (meaning you can do daily activities with little or no help).
- Your bladder cancer must have come back after previous treatment with BCG therapy, with or without mitomycin.
- You are considering or have been offered radical surgery (removal of the bladder) as a possible next treatment.
- You cannot have urinary incontinence, an active urine infection, or narrowing of the urethra.
- You cannot be taking blood thinners or anti-platelet medications.
- You must agree to use birth control during and for at least 3 months after the treatment (if you can become pregnant or are a male partner).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a new drug (IAP0971) given with BCG, a standard bladder treatment, to see if it helps people with high-risk bladder cancer that hasn't spread into the muscle. You may join if you've already tried BCG and it didn't work, and you're not having your bladder removed.
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
This trial tests a new drug, RAG-01, for people with a type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC) that has come back after BCG therapy. The drug is given through a catheter into the bladder, and the study aims to see if it can help control the cancer.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.